COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0E8HH
|
|||
Drug Name |
Fusion peptide EK1
|
|||
Synonyms |
EK1 peptide
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1] | Severe acute respiratory syndrome (SARS) | Investigative | [1] |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | MERS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) | Target Info | Inhibitor | [1] |
EK1, the optimized form of peptide OC43-HR2P, can form a stable six-helix bundle structure with HR1 of HCoV spike (S) protein, further supporting the role of HR1 region as a viable pan-CoV target site. EK1 shows substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties, including SARS-CoV and MERS-CoV. | ||||
SARS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) | Target Info | Inhibitor | [1] | |
EK1, the optimized form of peptide OC43-HR2P, can form a stable six-helix bundle structure with HR1 of HCoV spike (S) protein, further supporting the role of HR1 region as a viable pan-CoV target site. EK1 shows substantially improved pan-CoV fusion inhibitory activity and pharmaceutical properties, including SARS-CoV and MERS-CoV. |
References | Top | |||
---|---|---|---|---|
1 | A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.